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Background:Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited
toxicity, the recommended phase II dose (RP2D) was only tentatively defined.
Methods:We identified, by MEDLINE search, articles on single-agent trials of mAbs with an FIHT included in our previous survey.
For each mAb, we examined tested dose(s) and dose selection rationale in non-FIHTs (NFIHTs). We also assessed the correlation
between doses tested in the registration trials (RTs) of all FDA-approved mAbs and the corresponding FIHT results.
Results: In the 37 dose-escalation NFIHTs, the RP2D indication was still poorly defined. In phase II–III NFIHTs (n¼ 103 on 37
mAbs), the FIHT RP2D was the only dose tested for five mAbs. For 16 mAbs, only doses different from the FIHT RP2D or the
maximum administered dose (MAD) were tested and the dose selection rationale infrequently indicated. In the 60 RTs on 27 FDA-
approved mAbs with available FIHT, the FIHT RP2D was tested only for two mAbs, and RT doses were much lower than the FIHT
MAD.
Conclusions: The rationale beyond dose selection in phase II and III trials of mAbs is often unclear in published articles and not
based on FIHT data.
The main aim of first-in-human trials (FIHTs) is to explore the
safety of multiple escalating doses of a drug in order to identify the
highest dose associated with a tolerable toxicity. This is usually
defined as the maximum-tolerated dose (MTD) (Eisenhauer et al,
2000; Le Tourneau et al, 2009) and is frequently selected for the
subsequent drug development, on the basis of the assumption that
a positive correlation exists between the drug dose and its effect. It
is then indicated as the recommended phase II dose (RP2D) (Le
Tourneau et al, 2009). Available data convincingly showed that
FIHTs are the most important step in determining the dose of
FDA-approved anticancer drugs, because for most molecules the
RP2D is determined on the basis of the MTD, and the dose tested
in registration trials (RTs) is within 20% on either side of the RP2D
(Jardim et al, 2014). More uncertainty exists about dose selection
for targeted agents, because in this case, the RP2D coincides less
frequently with the MTD and predicts poorly the dose used in RTs
(Jardim et al, 2014). Indeed, designing and interpreting FIHTs for
targeted agents is difficult because of their limited acute toxicity
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(the first-cycle toxicity is usually the endpoint for MTD selection),
and because of the scarce correlation between pharmacokinetic
(PK) or pharmacodynamic (PD) parameters and drug efficacy in
this setting (Parulekar and Eisenhauer, 2004; Jardim et al, 2014;
Janne et al, 2016; Sweis et al, 2016). The challenge is even greater in
FIHTs of monoclonal antibodies (mAbs) due to the low risk of
acute toxicity associated with these molecules as a consequence of
their lack of off-target effects (Sachs et al, 2016), and also because
conventional FIHTs cannot capture the medium- and long-term
toxicity of tested drugs. We recently conducted a comprehensive
analysis of the design, implementation and outcome of FIHTs on
mAbs published between 2000 and 2013 (Tosi et al, 2015). We
found that, for most of the tested molecules, early-occurring
adverse events were rare and dose escalation could be continued up
to the highest planned dose level in all trials. Consequently, the
MTD could be identified only in a minority of trials. Conversely,
the RP2D was indicated in an important proportion of FIHTs,
mainly in the absence or independently of the MTD and on the
basis of PK or PD considerations. The PK data used to justify the
RP2D choice mostly relied on comparisons between the drug
concentrations found to be effective in preclinical studies and the
clinical PK findings. PD data often focused on receptor occupancy
assessment. However, the correlation between PK or PD
parameters in preclinical models and in patient samples is far
from being clearly established, which makes RP2D recommenda-
tions based on these observations at least doubtful. Despite these
uncertainties in RP2D selection, mAb clinical development
achieved several important successes for the treatment of
malignancies and immunologic disorders (Nelson et al, 2010);
however, comprehensive reviews are not available on the strategies
of mAb clinical testing following FIHTs.
The aim of this study was to evaluate the strategies of mAb
clinical development by analysing single-agent non-FIHTs
(NFIHTs) of mAbs the FIHT of which was included in our
previous analysis (Tosi et al, 2015), as well as the RTs of all FDA-
approved mAbs. After retrieving from MEDLINE all publications
on these NFIHTs and RTs, we examined the trial design and
results, with a particular focus on the relationship between FIHT
data and doses tested in these trials.
MATERIALS AND METHODS
Article search. In June 2016 we performed a MEDLINE search to
identify articles on single-agent trials of mAbs the FIHT of which
was included in our previous analysis (Tosi et al, 2015). Separately,
we identified mAbs approved as single agents by FDA up to 31
June 2016, and for each molecule we performed a MEDLINE
search (using all the known names of each drug) to identify the
FIHT and RTs. We excluded trials reporting on immunoconju-
gates, radioimmunoconjugates and non-systemic routes of admin-
istration (topical administration or ex-vivo treatment), trials on
Asian patients performed to confirm previous results obtained in
Western patients, phase III trials where the evaluated mAb was
used as standard treatment, as well as articles not written in
English language. The phase I and phase II parts of phase I/II
studies were analysed separately when possible.
Data collection and analysis. From articles on the NFIHTs of
mAbs with an FIHT included in our previous review (Tosi et al,
2015), we extracted treated disease, trial phase, rationale for dose(s)
selection, administration route, dose calculation unit, schedule,
presence of loading dose, tested dose(s), number of included
patients, and availability of PK or PD data. From dose escalation
trials, we also extracted the starting dose (SD), the maximum
planned dose, the maximum administered dose (MAD), the MTD,
the RP2D and the rationale for RP2D selection. For these trials, we
calculated the ratio between FIHT MAD and NFIHT MAD, the
ratio between NFIHT RP2D and FIHT MAD and the ratio between
NFIHT RP2D and FIHT RP2D. For phase II and III trials, we
calculated the ratio between the tested dose and FIHT MAD or
FIHT RP2D. For the analysis of the RTs concerning mAbs
approved by the FDA, we extracted treated disease, administration
route, dose calculation unit, schedule, presence of loading dose,
tested dose(s), number of included patients, and the three most
frequent grade 3/4 toxicities. From the relevant FIHT, we recorded
MAD, MTD, RP2D and the three most frequent grade 3/4
toxicities. We calculated the ratios between RT dose and FIHT
MTD and MAD, respectively. When more than one trial was
available for a given mAb in a data set, we used the mean of the
ratios from all the trials of this mAb to calculate summary statistics
on the dose ratios for the entire data set. We used descriptive
statistics to report whether the top-three grade 3/4 toxicities in the
RTs of each mAb were detected in the corresponding FIHT, and
their grade in the FIHT. Statistical analyses were performed with
the R software (version 3.3.2).
RESULTS
General results on NFIHTs. After reviewing the 139 articles
retrieved with the MEDLINE search, we selected for analysis 144
NFIHTs of 42 mAbs (1–15 NFIHTs for each molecule). The study
design and drug administration data of the selected NFIHTs are
shown in Table 1. Specifically, 39 studies (27%) were phase I and
103 (72%) phase II or III trials. Most trials concerned patients with
solid cancers or haematological malignancies (n¼ 111, 77%), while
the others focused mainly on immunologic disorders. In 131 trials
(91%), the mAb was administered only by intravenous route and a
loading dose was used in 20 (14%). For most mAbs, the same dose
calculation method was used in NFIHTs and the corresponding
FIHT. However, in 16 NFIHTs, a flat dose was administered
instead of the dose tested in the FIHT and calculated according to
weight (mg kg 1) or body surface (mgm 2).
Analysis of dose escalation NFIHTs. In 37 of the 39 of phase I
trials, a dose escalation procedure was implemented (for 21 mAbs).
We found that the highest planned dose corresponded to the FIHT
MAD for nine of the 19 (47%) mAbs tested in the NFIHTs that
used the FIHT dose calculation method. Indeed, the range of ratios
Table 1. Characteristics of the 144 NFIHTs included in the
study
Characteristic
Number of
trials (%)
Number of
mAbs
Trial phase
I 39 (27) 24
II 82 (57) 39
III 21 (15) 9
Not applicable 2 (1) 2
Disease type
Solid cancers 75 (52) 25
Haematological malignancies 36 (25) 13
Immunological/rheumatic diseases 32 (22) 13
Other diseases 1 (1) 1
Trials including a pharmacokinetic
study
74 (51) 34
Trials including a pharmacodynamic
study
81 (56) 36
Dose calculation
mg kg 1 87 (60) 28
mg m2 11 (8) 5
Flat dose 46 (32) 12
Abbreviations: NFIHT¼ non-first-in-human trial; mAb¼monoclonal antibody.
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between the highest NFIHT planned dose and FIHT MAD was
quite wide (0.1 to 6); however, for 15 mAbs (71%) in 21 trials
(65%) the highest planned dose level was lower or equal to the
FIHT MAD, and for 15 mAb (71%) in 19 trials (59%) it was within
33% on either side of the FIHT MAD (Figure 1). Like in the FIHT,
in all NFIHTs the mAb favourable safety profiles allowed dose
escalation up to the highest planned dose level that, therefore,
coincided with the MAD. An MTD was found for only seven of 21
mAbs (33%) tested in eighth (22%) dose escalation trials. An RP2D
was indicated for 11 of the 21 mAbs (52%) tested in 15 of the 37
NFIHTs (40%), but it matched the FIHT RP2D for only three
mAbs in four trials (Figure 1). The rationale for RP2D selection
was described for only 11 mAbs (Table 2) and was based on
considerations about safety (n¼ 6), PK (n¼ 4), and PD (n¼ 1).
The medians of the NFIHT RP2D/FIHT RP2D and NFIHT RP2D/
FIHT MAD ratios were 2.2 (range: 1 to 6) and 0.65 (range: 0.3
to 1), respectively.
Analysis of phase II and III NFIHTs. We then analysed the doses
tested in the 103 phase II and III trials (on 37 mAbs) with regard to
the FIHT results to assess FIHT data relevance for the subsequent
mAb development. First, we evaluated how the tested dose(s) was
selected (Table 3). A rationale was indicated for 26 mAbs (70%)
in 57 of the 103 trials (55%) and was based on the FIHT RP2D
(19 trials), PK data (7 trials), efficacy (7 trials), FIHT MAD
(4 trials), PD (2 trials), FIHT MTD (1 trial) or other considerations
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Figure 1. Relationship between NFIHT MAD, NFIHT RP2D and FIHT MAD for dose-escalating NFIHTs. (A) Ratio between the NFIHT MAD and
the FIHT MAD for each NFIHT with dose escalation. Each bar represents the ratio between the highest planned dose of each NFIHT and the
relevant FIHT. The names of tested mAb are indicated on the left. (B) Ratio between the NFIHT RP2D and the FIHT MAD for NFIHTs with dose
escalation. Filled circles represent the ratio between NFIHT RP2D and FIHT MAD. Each circle refers to a dose tested in one or more NFIHTs. The
names of tested mAb are indicated on the left. For comparison, hollow circles represent the ratio between RP2D and MAD in the corresponding
FIHT. FIHT=first-in-human trial; MAD=maximum administered dose; NFIHT=non-first-in-human trial; RP2D=recommended phase II dose.
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Table 2. Rationale for RP2D selection in trials with dose escalation
References mAb name
Dose
calculation
FIHT NFIHT
FIHT NFIHT RP2D MAD MAD MTD RP2D Rationale for RP2D selection
Baselga
et al, 2000
Tabernero
et al, 2010
Cetuximab mg m 2 100 qw 700
q2w
500
q2w
These data indicate that the closest PK
match to the weekly standard regimen
will be provided by every-second-week
administration of 500 or 600 mg m 2,
with 500 mg m 2 being the dose of
choice on this schedule in terms of
convenience and feasibility.
De Bono
et al, 2004
Goel et al,
2007
ING-1 mg m 2 0.1 qw 1 q3w 2 qw 0.6
qw
0.6 qw MTD
Mullamitha
et al, 2007
O’Day
et al, 2011
Intetumumab mg kg 1 10 d1, 29,
36, 43
20
q3w
10 q3w The clinical activity of the two dose
levels was very similar in this study with
the exception of the duration of grade
1 uveitic reaction after the first dose (7–
8 days in patients treated with
10 mg kg1 and 6–14 days in patients
treated with 20 mg kg 1). There was
no sequela in any patient. Based on
these results, it is recommended that
future studies with intetumumab
continue to include the 10 mg kg1
dose level.
Plummer
et al, 2007
Wakelee
et al, 2010
Lexatumumab mg kg 1 10 q3w 20 q3w 10
q2w
10 q2w Based on the previously determined
MTD of lexatumumab (10 mg kg1
every 21 days), escalation beyond
10 mg kg1 was not attempted.
Bensinger
et al, 2012
Byrd et al,
2007
Lucatumumab mg kg 1 6 qw 6 qw 3 qw 3 qw There was essentially 100% saturation
of CD40 molecules at the end of each
infusion for all dose groups, but this
saturation was lost prior to the
beginning of the next infusion in the
0.3 mg kg1 and 1.0 mg kg1 dose
cohorts. In the remaining three dose
cohorts (X3.0 mg kg 1), bound
lucatumumab remained on circulating
chronic lymphocytic leukaemia cells
between infusions.
Bensinger
et al, 2012
Fanale
et al, 2014
Lucatumumab mg kg 1 6 qw 6 qw 4 qw 4 qw MTD
Yamamoto
et al, 2010
Kurose
et al, 2015
Mogamulizumab mg kg 1 1 qw 1 qw 1 qw
 8
then
q1m
1 qw
 8
then
q1m
Although we did not find any dose-
limiting toxicity and did not detect
Treg depletion at the tumour site, we
did not perform dose escalation with
concentrations 41 mg kg1 because
we observed serious skin toxicities in
patients with adult T-cell leukaemia
during prolonged treatment for more
than 1 year with 1 mg kg1, and
because complete elimination of Tregs
in PBMCs was easily obtained with
0.1 mg kg 1.
Yamamoto
et al, 2010
Duvic et al,
2015
Mogamulizumab mg kg 1 1 qw 1 qw 1 qw
 4
1 qw
 4
MAD
Brahmer
et al, 2010
Ansell
et al, 2015
Nivolumab mg kg 1 10 q2w 3 d1,
28
then
q2w
3 d1,
28
then
q2w
MAD
Salles et al,
2012
Sehn et al,
2015
Obinutuzumab mg 1600/800
and 400/
400 d1, 8,
21 then
q3w
1200/2000
d1, 8, 21
then q3w
1200/
2000
qw
1000/
1000
qw
The observed plasma concentration
data across the cohorts indicated
substantially higher concentrations 14
days after completion of the induction
phase at doses of 1000 mg and 1200/
2000 mg, indicating target saturation.
Consequently, a dose of 1000 mg was
chosen for further clinical studies.
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(17 trials). We then examined the relationship between FIHT
RP2D and doses tested in NFIHTs (Figure 2). FIHT RP2Ds (one or
more for each mAb) were available for 12 of the 37 mAbs and were
tested for 11 mAbs, alone (n¼ 5 mAbs) or in association with
other doses (n¼ 6 mAbs). The FIHT MAD was tested for eight
mAbs (73%) in 17 trials (45%) of mAbs with available FIHT RP2D.
The ratio between the doses tested in NFIHTs and the
corresponding FIHT RP2Ds ranged from 0.1 to 5, and in 84% of
cases the tested dose/FIHT RP2D ratio was not within 33% on
either side of the FIHT RP2D (Figure 2). The FIHT MAD of 17
mAbs (46%) was tested alone or with other doses in 36 trials
(35%). Only doses different from the FIHT RP2D or MAD were
tested for 16 mAbs (43%) in 37 trials (36%). Finally, we verified
that the tested doses were included in the range established as safe
in the FIHT and compared them with the FIHT MAD (Figure 2).
Only in nine trials on two mAbs, the tested dose was higher than
the FIHT MAD. The median tested dose/FIHT MAD ratio was
0.71 (range: 0.25 to 2.5) in trials with comparable dose calculation
methods.
Analysis of the correlation of doses and toxicities in RTs and the
corresponding FIHT. We retrieved 27 FDA-approved mAbs with
a FIHT and 60 RTs on these molecules (Supplementary Table S1).
The mAb indication was cancer (solid tumours for eight mAbs,
haematological cancers for three mAbs), immune system diseases
(13 mAbs) and other diseases (four mAbs). The FIHT MTD was
available for only one molecule, whereas the FIHT RP2D was
indicated for seven mAbs (26%; five cancer trials and two other
trials). We then evaluated the relevance of the FIHT results for the
17 mAbs with the same dose calculation method in FIHT and RTs.
The RP2D was tested in RTs of five mAbs (but only in two with the
same schedule), and the MAD in RTs of four mAbs (Figure 3). The
median RT dose/FIHT MAD ratio was 0.78 (range: 0.1 to 2.5).
When considering the nine mAbs for which an RP2D was not
available, at least one RT dose was lower than 75% of the MAD for
six of them (specifically, lower than 50% for four mAbs and lower
than 25% for one). We determined whether the top-three grade 3/4
toxicities in the RTs of each mAb were reported in the
corresponding FIHT, and their grade in the FIHT. For only seven
Table 2. ( Continued )
References mAb name
Dose
calculation
FIHT NFIHT
FIHT NFIHT RP2D MAD MAD MTD RP2D Rationale for RP2D selection
Spratlin
et al, 2010
Chiorean
et al, 2015
Ramucirumab mg kg 1 8 q2w 16 q2w 20 8 q2w
or 10
q3w
Doses within this range yielded the
minimum trough concentrations that
exceeded the 20 mg ml1 levels
associated with growth inhibition in
preclinical human tumour xenograft
models and with preliminary evidence
of efficacy. In addition, doses of
X8 mg kg 1 Q2W were associated
with relatively stable clearance profiles
(as opposed to more dose-dependent
patterns seen at lower doses),
consistent with saturation of the target-
mediated clearance pathway.
Ribas, 2005 Camacho
et al, 2009
Tremelimumab mg kg 1 15 single
dose
10
q4w
15
every 3
months
During the phase II study, 89 patients
received 10 mg kg1 tremelimumab
once every month or 15 mg kg 1 every
3 months. The results of this study
supported the choice of the
15 mg kg 1 every 3 months regimen
for further clinical development. Within
the limitations of this non-comparative
phase II two-arm clinical trial, both
regimens were associated with durable
tumour responses, but 15 mg kg1
every 3 months was more convenient
to administer and was associated with
fewer and less severe/serious adverse
events.
Norman
et al, 2000
Plevy et al,
2007
Visilizumab mg kg 1 15 once 15 d1,
d2
10
d1,
d2
10 d1,
d2
MTD
Norman
et al, 2000
Carpenter
et al, 2002
Visilizumab mg m 2 15 mg kg 1
once
3 d1,
d3,
d5,
d7,
d9,
d11,
d13
3 d1,
d3, d5,
d7, d9,
d11,
d13
Our pharmacokinetic data suggest that
the size of the first dose of visilizumab
affects treatment outcome more than
the total cumulative dose. The rates of
complete response and survival were
higher after a single dose of 3 mg m 2
compared with 7 doses of 0.25 or
1.0 mg m2 where the cumulative dose
administered was 1.75 mg m 2 or
7 mg m2.
Norman
et al, 2000
Baumgart
et al, 2010
Visilizumab mg kg 1 15 once 12.5
d1, d2
5 d1,
d2
Chosen as the optimal clinical dose
because of comparable efficacy and
less toxicity than with higher doses.
Abbreviations: FIHT¼ first-in-human trial; mAb¼monoclonal antibody; MAD¼maximum administered dose; MTD¼maximum tolerated dose; NFIHT¼non-first-in-human trial; RP2D¼
recommended phase II dose; qw¼one a week; q2w¼ every 2 weeks; q3w¼ every 3 weeks; q4w¼ every 4 weeks.
Strategies for clinical development of mAbs BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.473 683
Table 3. Rationale for tested dose selection in NFIHT without dose escalation
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
Oberneder
et al, 2006
Schmidt et al, 2010 Adecatumumab 262 mg m2 q2w 164 mg m 2 q2w,
262 mg m2 q2w
2, 6 mg kg1 q2w See details The dosage regimen and
treatment duration selected
for this study were based on
PK modelling of the phase I
clinical study results in
patients with prostate cancer.
Oberneder
et al, 2006
Marschner et al, 2010 Adecatumumab 262 mg m2 q2w 164 mg m 2 q2w,
262 mg m2 q2w
2, 6 mg kg1 qw
 3 then q2w 
7
See details A phase I trial in patients with
hormone-refractory prostate
cancer showed that
adecatumumab is well
tolerated with low
immunogenicity at doses up
to 262 mg m2
(approximately 6.6 mg kg1)
every other week.
Furie et al,
2008
Bishton et al, 2013 Belimumab 20 mg kg1 q3w 10 mg kg 1 d1,
15 q28 then q28
See details These belimumab levels are
sufficient to neutralise the
cytokine BLYS and are similar
to those achieved in studies
conducted in systemic lupus
erythematous, in which an
average peak concentration
of 192.4 mg ml1 was
achieved at a 10 mg kg 1
dose level.
Furie et al,
2008
Wallace et al, 2009,
De Vita et al, 2015
Belimumab 20 mg kg1 q3w 10 mg kg 1 d1,
15 q28 then q28
NA
Gordon
et al, 2001
Ogita et al, 2012,
Schuster et al, 2012
Bevacizumab 10 mg kg 1 d1,
d28, d35, d42
10 mg kg1 q2w See details The chosen dose was higher
than the doses used in
bevacizumab therapies for
normalisation of tumour
vasculature (5 mg kg1 q14d)
and in line with the dosing of
bevacizumab monotherapy
used in advanced renal
cancer where a survival
benefit was indicated
(10 mg kg 1 q14d).
Baselga
et al, 2000
Cunningham et al,
2004, Pessino et al,
2007, Neal et al,
2010, Tabernero et al,
2010, Maubec et al,
2011, Wierzbicki et al,
2011, Segelov et al,
2016
Cetuximab 100 mg m2 qw 250 mg m2 qw NA
Atzori et al,
2011
Reidy-Lagunes et al,
2012
Dalotuzumab 20 mg kg1 qw 10 mg kg1 qw,
20 mg kg1 q2w,
30 mg kg1 q3w
10 mg kg1 qw RP2D in FIHT
Trachtman
et al, 2011
Stevenson et al, 2013 Fresolimumab 4 mg kg1 single
dose
3 mg kg1 q3w See details This dose was chosen based
on non-human primate
studies and data from the
previous phase I trial in
cancer, where an MTD up to
15 mg kg1 was established,
but clinical responses were
observed in patients at doses
of 1 mg kg 1 or lower.
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Table 3. ( Continued )
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
Tolcher et al,
2009
Tap et al, 2012 Ganitumab 20 mg kg1 q2w 12 mg kg1 q2w See details In the FIHT, this regimen was
tolerated, with a mean serum
trough concentration
(42 mg ml 1) that exceeded
the 90% inhibitory
concentration (28mg ml1) in
a human MiaPaCa-2 cell
xenograft model and
provided 90% IGF1R
receptor occupancy in a
surrogate tissue assay.
Tolcher et al,
2009
Strosberg et al, 2013 Ganitumab 20 mg kg1 q2w 18 mg kg1 q3w NA
Scott et al,
2007
Krug et al, 2007 hu3S193 40 mg m2 qw 10, 20 mg m2
qw
NA
Vey et al,
2012
Korde et al, 2014 IPH2101 3 mg kg1 q4w 1 mg kg1 q2m NA
Genovese
et al, 2010
Leonardi et al, 2012 Ixekizumab 2 mg kg1 q2w 10, 25, 75,
150 mg q2w 2
then q4w  3
NA
Genovese
et al, 2010
Gordon et al, 2014 Ixekizumab 2 mg kg1 q2w 120 mg q1m NA
Genovese
et al, 2010
Genovese et al, 2014 Ixekizumab 2 mg kg1 q2w 80 mg q2w (12w)
then q4w
NA
Tolcher et al,
2009
Greco et al, 2008,
Trarbach et al, 2010
Mapatumumab 10 mg kg1 q14 10 mg kg1 q3w See details The MTD was not identified
at doses up to 20 mg kg 1
administered every 28 days.
Stable disease was observed
in a number of heavily
pretreated patients at several
dose levels. Therefore,
10 mg kg1 was considered a
safe and potentially effective
dose for the treatment of
non-small cell lung cancer.
Vanhoefer,
2003
Seiden et al, 2007 Matuzumab 2000 mg qw 800 mg qw NA
Yamamoto
et al, 2010
Ishida et al, 2012 mogamulizumab 1 mg kg1 qw 1 mg kg1 qw 1 mg kg1 qw RP2D in FIHT
Brahmer
et al, 2010
Gardiner et al, 2013,
Borghaei et al, 2015,
Brahmer et al, 2015,
Hamanishi et al, 2015,
Motzer et al, 2015a,
2015b, Rizvi et al,
2015, Robert et al,
2015, Weber et al,
2015
Nivolumab 10 mg kg1 q2w 3 mg kg1 q2w NA
Salles et al,
2012
Morschhauser et al,
2013, Salles et al,
2013
Obinutuzumab 1200/2000 mg
d1, 8, 21, then
q3w
400/400, 1600/
800 mg d1, 8, 21,
then q3w
400/400, 1600/
800 mg d1, 8, 21,
then q3w
RP2D in FIHT We based the dose and
schedule of nivolumab on
safety and activity data from a
phase 1 study that showed a
similar proportion of
objective responses in
patients treated with
3 mg kg1 or with
10 mg kg1; both doses
achieved better responses
than the 1 mg kg 1 dose.
The safety profile was similar
with each dose and for
different tumour types in the
phase 1 trial.
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Table 3. ( Continued )
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
Salles et al,
2012
Cartron et al, 2014,
Byrd et al, 2016
Obinutuzumab 1200/2000 mg
d1, 8, 21, then
q3w
400/400, 1600/
800 mg d1, 8, 21,
then q3w
1000 mg d1, 8, 15
then q3w
NA
Forero-
Torres et al,
2012
Ganjoo et al, 2015 Ocaratuzumab 375 mg m2 qw 375 mg m2 qw See details Phase 2 dose selection was
based on safety and
preliminary efficacy data and
on modelling and simulation
of PK data. The latter showed
faster elimination of
obinutuzumab in the first
cycle than in later cycles,
indicating the need for a
more dose-dense regimen in
the first cycle.
Genovese
et al, 2008
Kappos et al, 2011 Ocrelizumab 750 mg m2 q3w 300/600,
1000 mg d1, 15
then q24w
NA The maximum ocaratuzumab
dose of 375 mg m2 was
tested to support subsequent
testing against rituximab at
an equivalent dose.
Hagenbeek
et al, 2008
Wierda et al, 2010 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
300/2000 mg qw
 8 then q4w 
4
NA
Hagenbeek
et al, 2008
Coiffier et al, 2013 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
300/1000 mg qw RP2D in FIHT
Hagenbeek
et al, 2008
Czuczman et al, 2012 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
500, 1000 mg qw RP2D in FIHT
Hagenbeek
et al, 2008
Furtado et al, 2014 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
1000 mg qw RP2D in FIHT
Hagenbeek
et al, 2008
van Oers et al, 2015 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
1000 mg qw  1
then q8w
NA
Hagenbeek
et al, 2008
Taylor et al, 2011 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
700 mg q2w  2 NA
Hagenbeek
et al, 2008
O¨sterborg et al, 2016 Ofatumumab 1000 mg qw 500 mg qw,
1000 mg qw
2000 mg qw  8
then qm
NA A phase I/II study of
ofatumumab, administered
as two intravenous infusions
of 300, 700 or 1000 mg per 2
weeks apart, in patients with
active rheumatoid arthritis
and inadequate response to
disease-modifying anti-
rheumatic drugs
demonstrated significant
clinical benefit and
reasonable tolerability at all
doses investigated compared
with placebo. The 700 mg
dose was considered
optimal.
Emu et al,
2012
Kennedy et al, 2014 Pateclizumab 3 mg q2w 360 mg q2w See details Based on safety and efficacy
data from a phase I/II study in
patients with chronic
lymphocytic leukaemia.
Agus, 2005 Gordon et al, 2006,
De Bono et al, 2007,
Gianni et al, 2010
Pertuzumab 15 mg kg1 q3w 420 mg q3w 840/420,
1050 mg q3w
MAD and
RP2D in FIHT
This study regimen was
selected based on the
following considerations: (1)
total exposure was, on
average, 60% higher than
with the 3 mg kg 1 biweekly
subcutaneaously doses
evaluated in the
pateclizumab phase I study;
(2) this regimen was expected
to result in a maximal
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Table 3. ( Continued )
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
pharmacological effect as
suggested by plateaued
reductions in serum CXCL13
level in all dose groups at
1 mg kg1 or higher doses;
and (3) this regimen has 2.2-
to 4.5-fold exposure safety
coverage by the highest
exposure level assessed in
the phase I study.
Agus, 2005 Agus et al, 2007 Pertuzumab 15 mg kg1 q3w 420 mg q3w 840/420 mg q3w RP2D in FIHT Pertuzumab infusions every 3
weeks at doses
X5.0 mg kg1 maintained
serum concentrations in
excess of 20mg ml 1. Dose–
response studies of
pertuzumab in non-clinical
models showed that more
than 80% suppression of
tumour growth is achieved at
steady-state trough
concentrations of 5–
25 mg ml1. The
recommended regimen for
phase II testing was therefore
a fixed dose of 420 mg
(equivalent to 6 mg kg 1 for
a 70-kg patient) every 3
weeks. However, using this
regimen, steady-state
concentrations are only
attained after about 90 days.
A loading dose of 840 mg
was therefore recommended.
Simulated trough
concentrations for
pertuzumab predicted that
with a fixed dose of 1050 mg
(equivalent to a dose of
15 mg kg1 for a 70-kg
patient; the highest dose
studied in phase I trials), 90%
of patients would achieve
steady-state trough
concentrations
X28.8 mg ml1. This dose
was used because preclinical
studies suggested a dose-
dependent increase in
efficacy.
Agus, 2005 Herbst et al, 2007 Pertuzumab 15 mg kg1 q3w 420 mg q3w 840/420 mg q3w RP2D in FIHT
Berger et al,
2008
Armand et al, 2013 Pidilizumab 6 mg kg1 single
dose
1 mg kg1 single
dose
1.5 mg kg1 q42 NA
Dı´az et al,
2003
Alfonso et al, 2007 Racotumomab 2 mg q2w 1 mg q2w  5
then q4w
NA
Dı´az et al,
2003
Alfonso et al, 2014 Racotumumab 2 mg q2w 1 mg q2w  5
then q4w  10
NA
Dı´az et al,
2003
Neninger et al, 2007 Racotumumab 2 mg q2w 2 mg q2w  5
then q4w 6
NA
Spratlin
et al, 2010
Zhu et al, 2013, Fuchs
et al, 2014, Garcia
et al, 2014, Penson
et al, 2014
Ramucirumab 16 mg kg 1 d1,
15 then q2w
8 mg kg1 d1, 15
then q2w
8 mg kg1 q2w RP2D in FIHT
Spratlin
et al, 2010
Carvajal et al, 2014 Ramucirumab 16 mg kg 1 d1,
15 then q2w
8 mg kg1 d1, 15
then q2w
10 mg kg1 q3w NA A phase II dose of 8 mg kg 1
every 2 weeks was selected
because it was associated
with the minimum drug
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Table 3. ( Continued )
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
concentrations that
exceeded the levels
associated with tumour
growth inhibition in
preclinical models and with
PK profiles suggesting
receptor saturation, and
because preliminary efficacy
was observed across a range
of phase I doses and
schedules.
Paz-Ares
et al, 2011
Delord et al, 2014 RGT160 1400 mg d1, d8
then q2w
1400 mg d1, d8
then q2w
1400 mg d1, d8
then q2w
RP2D
Gordon
et al, 2010
Scho¨ffski et al, 2011,
Wen et al, 2011
Rilotumumab 20 mg kg 1 d1,
29 then q2w
10 mg kg1 q2w,
15 mg kg1 q3w,
20 mg kg1 q4w
10, 20 mg kg1
q2w
MAD and
RP2D in FIHT
Bartlett et al,
2008
Forero-Torres et al,
2010
SGN-30 12 mg kg1 qw 6 mg kg1 qw 6, 12 mg kg1 qw
 6 then 2 weeks
off
MAD in FIHT,
see details
Bartlett et al,
2008
Duvic et al, 2009 SGN-30 12 mg kg1 qw 6 mg kg1 qw 4, 12 mg kg1
q2w/q3w
See details Based on the assessment of
rilotumumab serum
concentration in the FIHT and
values of 90% inhibitory
concentrations predicted in
U-87 MG glioblastoma cell
proliferation assays,
10 mg kg1 was selected as
the starting dose.
Scott et al,
2003
Hofheinz et al, 2003 Sibrotuzumab 50 mg m2 qw 100 mg qw NA The first 40 patients enrolled
in the study (15 in the
Hodgkin lymphoma group
and 25 in the anaplastic large
cell lymphoma group)
received SGN-30 at
6 mg kg1 weekly. To
increase the objective
response rates and after an
interim analysis of the safety
data and review of the
response data from the
previous phase I study, SGN-
30 dose was increased to
12 mg kg1 weekly for the
remaining patients.
Rosen et al,
2012
Duffy et al, 2015 TRC105 15 mg kg1 qw 10 mg kg1 qw or
15 mg kg1 q2w
15 mg kg1 q2w RP2D The first six patients enrolled
received six doses (one
course) of SGN-30 at
4 mg kg1 administered as
i.v. infusion every 2–3 weeks.
If there was no response, the
dose could be increased to
12 mg kg1. A protocol
amendment increased the
starting dose to 12 mg kg 1,
which was given to 17
patients.
Herbst et al,
2009
D’ Angelo et al, 2015 Trebananib 30 mg kg1 qw 30 mg kg1 qw 30 mg kg1 qw RP2D in FIHT
Herbst et al,
2009
Moore et al, 2015 Trebananib 30 mg kg1 qw 30 mg kg1 qw 15 mg kg1 qw NA
Ribas, 2005 Chung et al, 2010,
Kirkwood et al, 2010,
Ralph et al, 2010,
Sangro et al, 2013
Tremelimumab 15 mg kg1
single dose
15 mg kg1 q90 NA
Norman
et al, 2000
Carpenter et al, 2005 Visilizumab 0.015 mg kg 1
(once)
3 mg m2 single
dose
NA
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mAbs (25%) at least two of the top-three RT grade 3/4 toxicities were
reported as grade 3/4 in FIHT. Conversely, for 16 (57%) none of the
top-three grade 3/4 toxicities described in the RTs was reported as
grade 3/4 in FIHT. In addition, for seven (25%) of mAbs none of the
top-three grade 3/4 toxicities was reported in FIHT.
DISCUSSION
In our previous analysis concerning the FIHTs of mAbs published
between 2000 and 2013, we showed that, for most of the tested
molecules, acute toxicity events were rarely observed and did not
allow the identification of an MTD. This frequently led to doubtful
or questionable recommendations about the RP2D that was
determined on the basis of surrogate endpoints (Tosi et al,
2015). Here, we analysed the NFIHTs of the same mAbs to
evaluate how these trials used the FIHT-derived results, particu-
larly the FIHT RP2D and MAD. We also investigated whether the
FIHT results were relevant in the case of FDA-approved mAbs,
relative to the tested doses and toxicities observed in RTs.
In the examined dose escalation NFIHTs, the dose level scheme
was conservative relative to the FIHT, severe toxicities were
infrequent, the MTD was rarely determined and the RP2D was
indicated in a minority of trials. In addition, the rationale for RP2D
selection was infrequently available and not always stringent, when
present. These results indicate that even when a dose escalation
trial for an mAb is performed in post-FIHT settings, a significant
uncertainty persists over the RP2D indication. Moreover, we found
that the FIHT RP2D had a limited influence on dose selection in
phase II–III NFIHTs. This is in striking contrast with what
generally occurs in anticancer drug development, where the final
FDA-approved dose is within 20% on either side of the FIHT
RP2D in 73% of cases (Jardim et al, 2014). In addition, the FIHT
MAD was frequently tested in trials of mAb with available RP2D,
suggesting a lack of confidence in the RP2D selection criteria. On
the other hand, the FIHT MAD constituted a widely accepted
upper limit for dose selection in phase II–III NFIHTs. Frequently,
we could not retrieve a convincing justification for dose selection in
NFIHTs of mAbs. In a significant percentage of trials, the dose
tested in NFIHTs without dose escalation did not correspond to
the RP2D or MAD and no rationale for dose selection was
available, which did not allow evaluating whether the assumptions
underlying the choice were appropriate. When the FIHT RP2D or
MAD was not used to inform decisions about the dose to be tested
in NFIHTs, preclinical data on the drug effective concentration and
clinical PK data were frequently the parameters of choice, notably
the serum concentrations attained in clinical trials. However, due
to their size, mAb penetration in tissues occurs mainly by
convective transport and is characterised by slow diffusion rates
in tumour tissue (Tabrizi et al, 2010; Dostalek et al, 2013; Tibbitts
et al, 2016). This poor tumour uptake is mostly explained by the
scarce tumour vascularisation and the increased interstitial fluid
pressure, secondary to vessel abnormalities, fibrosis and interstitial
matrix contraction (Heldin et al, 2004). Consequently, it appears
hazardous to simply infer the mAb tumour tissue concentration
from their serum level.
The lack of association between the most frequent severe
toxicities in FIHT and RTs suggests that the FIHT results are not
useful to predict the actual mAb toxicity and that, consequently, an
approach based on a toxicity-guided dose selection during the early
clinical development of mAbs could be misguiding. Moreover, the
Table 3. ( Continued )
References mAb name FIHT NFIHT
FIHT NFIHT MAD RP2Ds Dose
Rationale
for dose
selection
Rationale for dose
selection, details
Norman
et al, 2000
Sandborn et al, 2010 Visilizumab 0.015 mg kg 1
(once)
5 mg kg 1 d1, d2 See details A phase I/II trial was
conducted to evaluate the
safety and efficacy of multi-
dose tremelimumab
regimens. In the phase II
portion of the study, patients
(n¼89) received 15 mg kg1
administered every 90 days
or 10 mg kg 1 every month.
The 15 mg kg 1 every 90
days regimen was selected
for further development
based on the incidence of
grade 3/4 adverse events
(13% with 15 mg kg1 every
90 days vs and 27% with
10 mg kg1 every month,
respectively) and serious
adverse events (9% and
25%).
Ricart et al,
2008
Bell-McGuinn et al,
2011
Volociximab 15 mg kg 1 d1,
15, 22, 29, 36
then qw
15 mg kg1 qw MAD in FIHT In a phase I study, visilizumab
was well tolerated in patients
with steroid-resistant acute
graft vs host disease, and
improvement was
documented in 10 of 11
patients who received a
single dose (3 mg m 2) of
visilizumab.
Abbreviations: FIHT¼ first-in-human trial; mAb¼monoclonal antibody; MAD¼maximum administered dose; MTD¼maximum tolerated dose; NFIHT¼ non-first-in-human trial; PK¼
pharmacokinetics; RP2D¼ recommended phase II dose; qw¼one a week; q2w¼ every 2 weeks; q3w¼ every 3 weeks; q4w¼every 4 weeks; qm¼ every month.
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absence of significant toxicity in FIHTs could complicate the
choice of the doses to be tested in later trials. Selecting an
unnecessarily high mAb dose can be unsafe because rare dose-
dependent toxicities could appear later during the drug develop-
ment process. Inappropriately low doses also can affect efficacy and
tolerability because, in the presence of an abundant target mass, the
mAb PK could be altered due to target-mediated drug disposition
(Cartron et al, 2016; Meulendijks et al, 2016), especially when the
mAb target is also expressed in healthy tissues (Azzopardi et al,
2011).
Other approaches for optimal mAb dose selection could be
suggested, such as correlating the mAb serum concentration with
PD marker variations, or implementing PK/PD models. The choice
and accessibility to the measured PD markers are crucial in this
setting. Quantitative data on serum (soluble) mAb targets, receptor
occupancy on circulating tumour cells, serum markers that
indirectly reflect the mAb effect (Mayer et al, 2015), or clinical
parameters directly linked to disease activity (Azzopardi et al,
2015) represent useful PD endpoints for clinical trials. However,
for mAbs that alter intracellular signalling, PD marker assessment
in tumour cells is an elusive endpoint due to the limited availability
of repeated biopsies. Integrative evaluations, including gene
expression and phosphokinome profiling in tumour samples and
liquid biopsies, could represent suitable tools for dose-finding
clinical trials when preclinical studies have established clear
correlations between a molecular signature and drug efficacy.
In addition, we previously showed that in mAb FIHTs the safety
data relevant for dose selection are collected during a short
observation window, which frequently corresponds to the first
cycle of treatment (Tosi et al, 2015). Indeed, mAb PK could be
far from the steady state throughout this time, because of the long
drug half-life and dosing schedules that are frequently at least
weekly (Tosi et al, 2015). In addition, the effect of target-mediated
drug disposition (Azzopardi et al, 2011), and the rare administra-
tion of loading doses (Tosi et al, 2015) could contribute to
delay reaching the maximal serum concentrations. Consequently,
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Figure 2. Ratio between the phase II/III NFIHT doses and the FIHT MAD. (A) Ratio between the dose tested in NFIHT and the FIHT MAD for each
mAb without an FIHT RP2D. Circles represents the ratio between the tested dose of each mAb and the relevant FIHT MAD. Each circle refers to a
dose tested in one or more NFIHTs. The names of tested mAb are indicated on the left. (B) Ratio between the dose tested in NFIHT and the FIHT
MAD for each mAb with an FIHT RP2D. Hollow circles represent the ratio between the tested dose of each mAb and the relevant FIHT MAD. Each
circle refers to a dose tested in one or more NFIHTs. Filled circles represent the ratio between the FIHT RP2D and the FIHT MAD. The names of
tested mAb are indicated on the left. FIHT=first-in-human trial; MAD=maximum administered dose; NFIHT=non-first-in-human trial;
RP2D=recommended phase II dose.
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safety data or PK or PD evaluations obtained in this setting have
limited value, suggesting that trial designs including a longer time
frame for endpoint assessment at selected doses could be more
appropriate.
CONCLUSIONS
We show that the results of FIHTs, particularly standard FIHT
endpoints such as MAD, MTD and RP2D, are frequently not taken
into account for the design of later clinical studies on mAbs.
Moreover, while safety is the main endpoint of mAb FIHTs, other
pharmacological aspects are often considered for dose choice in
later clinical trials, although the relevance of these surrogate
endpoints relative to the mAb clinical activity is questionable. New
clinical development strategies are urgently needed for this class of
molecules characterised by scarce toxicity, specific PK and high
therapeutic potential. Particularly, these data strongly support
shorter and more PD-focused phase I studies, as well as
randomised phase II studies to compare different mAb doses.
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Figure 3. Ratio between RT doses and FIHT MAD. (A) Ratio between the dose tested in RT and the FIHT MAD for each mAb without an
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